213 related articles for article (PubMed ID: 24782344)
1. A new proportion measure of the treatment effect captured by candidate surrogate endpoints.
Kobayashi F; Kuroki M
Stat Med; 2014 Aug; 33(19):3338-53. PubMed ID: 24782344
[TBL] [Abstract][Full Text] [Related]
2. Proportion of treatment effect mediated by surrogate endpoints.
Kuroki M; Shingaki R; Qu Y
Biom J; 2021 Jan; 63(1):105-121. PubMed ID: 33200481
[TBL] [Abstract][Full Text] [Related]
3. Alternative methods to evaluate trial level surrogacy.
Abrahantes JC; Shkedy Z; Molenberghs G
Clin Trials; 2008; 5(3):194-208. PubMed ID: 18559408
[TBL] [Abstract][Full Text] [Related]
4. A measure of the proportion of treatment effect explained by a surrogate marker.
Wang Y; Taylor JM
Biometrics; 2002 Dec; 58(4):803-12. PubMed ID: 12495134
[TBL] [Abstract][Full Text] [Related]
5. Statistical challenges in the evaluation of surrogate endpoints in randomized trials.
Molenberghs G; Buyse M; Geys H; Renard D; Burzykowski T; Alonso A
Control Clin Trials; 2002 Dec; 23(6):607-25. PubMed ID: 12505240
[TBL] [Abstract][Full Text] [Related]
6. An entropy-based nonparametric test for the validation of surrogate endpoints.
Miao X; Wang YC; Gangopadhyay A
Stat Med; 2012 Jun; 31(14):1517-30. PubMed ID: 22344829
[TBL] [Abstract][Full Text] [Related]
7. How to use frailtypack for validating failure-time surrogate endpoints using individual patient data from meta-analyses of randomized controlled trials.
Sofeu CL; Rondeau V
PLoS One; 2020; 15(1):e0228098. PubMed ID: 31990928
[TBL] [Abstract][Full Text] [Related]
8. Inference for Surrogate Endpoint Validation in the Binary Case.
Bebu I; Mathew T; Agan B
J Biopharm Stat; 2015; 25(6):1272-84. PubMed ID: 25616958
[TBL] [Abstract][Full Text] [Related]
9. Exploring the relationship between the causal-inference and meta-analytic paradigms for the evaluation of surrogate endpoints.
Van der Elst W; Molenberghs G; Alonso A
Stat Med; 2016 Apr; 35(8):1281-98. PubMed ID: 26612787
[TBL] [Abstract][Full Text] [Related]
10. Surrogacy assessment using principal stratification when surrogate and outcome measures are multivariate normal.
Conlon AS; Taylor JM; Elliott MR
Biostatistics; 2014 Apr; 15(2):266-83. PubMed ID: 24285772
[TBL] [Abstract][Full Text] [Related]
11. A reflection on the causal interpretation of individual-level surrogacy.
Alonso A; Van Der Elst W; Molenberghs G; Florez AJ
J Biopharm Stat; 2019; 29(3):529-540. PubMed ID: 30773114
[TBL] [Abstract][Full Text] [Related]
12. surrosurv: An R package for the evaluation of failure time surrogate endpoints in individual patient data meta-analyses of randomized clinical trials.
Rotolo F; Paoletti X; Michiels S
Comput Methods Programs Biomed; 2018 Mar; 155():189-198. PubMed ID: 29512498
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of surrogate endpoints in randomized experiments with mixed discrete and continuous outcomes.
Molenberghs G; Geys H; Buyse M
Stat Med; 2001 Oct; 20(20):3023-38. PubMed ID: 11590630
[TBL] [Abstract][Full Text] [Related]
14. Is blood pressure reduction a valid surrogate endpoint for stroke prevention? An analysis incorporating a systematic review of randomised controlled trials, a by-trial weighted errors-in-variables regression, the surrogate threshold effect (STE) and the Biomarker-Surrogacy (BioSurrogate) Evaluation Schema (BSES).
Lassere MN; Johnson KR; Schiff M; Rees D
BMC Med Res Methodol; 2012 Mar; 12():27. PubMed ID: 22409774
[TBL] [Abstract][Full Text] [Related]
15. An information-theoretic approach for the evaluation of surrogate endpoints based on causal inference.
Alonso A; Van der Elst W; Molenberghs G; Buyse M; Burzykowski T
Biometrics; 2016 Sep; 72(3):669-77. PubMed ID: 26864244
[TBL] [Abstract][Full Text] [Related]
16. Statistical controversies in clinical research: an initial evaluation of a surrogate end point using a single randomized clinical trial and the Prentice criteria.
Heller G
Ann Oncol; 2015 Oct; 26(10):2012-6. PubMed ID: 26254442
[TBL] [Abstract][Full Text] [Related]
17. Validation of surrogate markers in multiple randomized clinical trials with repeated measurements: canonical correlation approach.
Alonso A; Geys H; Molenberghs G; Kenward MG; Vangeneugden T
Biometrics; 2004 Dec; 60(4):845-53. PubMed ID: 15606404
[TBL] [Abstract][Full Text] [Related]
18. Meta-analyses evaluating surrogate endpoints for overall survival in cancer randomized trials: A critical review.
Savina M; Gourgou S; Italiano A; Dinart D; Rondeau V; Penel N; Mathoulin-Pelissier S; Bellera C
Crit Rev Oncol Hematol; 2018 Mar; 123():21-41. PubMed ID: 29482777
[TBL] [Abstract][Full Text] [Related]
19. Surrogate markers and joint models for longitudinal and survival data.
Taylor JM; Wang Y
Control Clin Trials; 2002 Dec; 23(6):626-34. PubMed ID: 12505241
[TBL] [Abstract][Full Text] [Related]
20. Validation of surrogate endpoints in cancer clinical trials via principal stratification with an application to a prostate cancer trial.
Tanaka S; Matsuyama Y; Ohashi Y
Stat Med; 2017 Aug; 36(19):2963-2977. PubMed ID: 28485043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
